KPV, a tripeptide composed of lysine, proline, and valine, is derived from the neuroimmunomodulatory peptide alpha-melanocyte-stimulating hormone. Researchers primarily study KPV for its anti-inflammatory properties and potential therapeutic applications in various inflammatory conditions, including vitiligo and colitis. Key findings indicate that KPV can modulate inflammatory responses by inhibiting the NLRP3 inflammasome in melanocytes, thereby reducing inflammation and pyroptosis, while also demonstrating enhanced gastrointestinal stability and bioavailability when delivered via innovative peptide prodrug conjugates. Current research continues to explore KPV's mechanisms of action and its effectiveness in preclinical models, highlighting its promise as a candidate for addressing inflammatory disorders.